Clinical Trial

Phase 3 vascular outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (PAD) (Acronym: VOYAGER PAD (Protocol BAY 59-7939/17454)

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

Purpose of the study is to evaluate the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures.


Principal Investigator Mahesh Changlani, MD
Sponsor Bayer Health Care Pharmaceuticals, Inc.
Type of Trial Interventional